| Autor: |
Kim WJ; Center for Controlled Chemical Delivery, Department of Pharmaceutics and Pharmaceutical Chemistry, 20 S 2030 E RM 205 BPRB, University of Utah, Salt Lake City, UT 84112-5820, USA., Yockman JW, Jeong JH, Christensen LV, Lee M, Kim YH, Kim SW |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2006 Sep 12; Vol. 114 (3), pp. 381-8. Date of Electronic Publication: 2006 Jun 07. |
| DOI: |
10.1016/j.jconrel.2006.05.029 |
| Abstrakt: |
Vascular endothelial growth factor (VEGF) is an endogenous mediator of tumor angiogenesis. Blocking associations of the VEGF with its corresponding receptors (Flt-1, KDR/flk-1) have become critical for anti-tumor angiogenesis therapy. Previously, we synthesized PEI-g-PEG-RGD conjugate and evaluated as an angiogenic endothelial polymeric gene carrier. In this study, PEI-g-PEG-RGD/pCMV-sFlt-1 complexes are evaluated in terms of tumor growth inhibition in vivo. Complexes were repeatedly injected systemically via tail vein into subcutaneous tumor-bearing mice. As a result, tumor growth was inhibited in the PEI-g-PEG-RGD/pCMV-sFlt-1 injected group. However, this effect was not identified in PEI-g-PEG/pCMV-sFlt-1 or PEI-g-PEG-RGD/pCMV-GFP control groups. Moreover, the survival rate increased in the PEI-g-PEG-RGD/pCMV-sFlt-1 group compared with the controls group. These results suggest that delivery of pCMV-sFlt-1 using PEG-g-PEG-RGD may be effective for anti-angiogenic gene therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect